SecSonar.com

Oculis Holding AG (OCS)

Oculis Holding AG at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Oculis Holding AG (OCS) is a Biotechnology company based in CH with a market capitalization of $1.7B. Free cash flow was negative at -$77.8M. This page tracks OCS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

CH · 49 employees · IPO May 18, 2021

Valuation

Valuation & price

$30.29 · as of May 17, 2026 · -7.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

8.42

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$32.64$21.81$10.98Jul 25Dec 25Jul 26Jul 7, 25$18.74Jul 9, 25$18.43Jul 11, 25$18.06Jul 15, 25$17.89Jul 17, 25$18.17Jul 21, 25$17.50Jul 23, 25$18.09Jul 25, 25$17.71Jul 29, 25$18.10Jul 31, 25$17.64Aug 4, 25$17.94Aug 6, 25$18.20Aug 11, 25$17.97Aug 13, 25$18.05Aug 15, 25$17.90Aug 19, 25$17.95Aug 21, 25$17.80Aug 25, 25$17.79Aug 27, 25$17.33Aug 29, 25$16.13Sep 3, 25$16.36Sep 5, 25$17.22Sep 9, 25$17.19Sep 11, 25$17.22Sep 16, 25$17.66Sep 18, 25$17.40Sep 22, 25$17.73Sep 24, 25$17.72Sep 26, 25$17.63Sep 30, 25$17.58Oct 2, 25$17.47Oct 6, 25$18.56Oct 8, 25$19.87Oct 10, 25$21.09Oct 14, 25$21.54Oct 16, 25$21.55Oct 21, 25$21.82Oct 23, 25$21.35Oct 27, 25$21.56Oct 29, 25$21.55Oct 31, 25$19.28Nov 4, 25$19.27Nov 6, 25$19.41Nov 10, 25$19.42Nov 12, 25$18.90Nov 14, 25$19.60Nov 18, 25$19.29Nov 20, 25$19.22Nov 25, 25$19.33Nov 28, 25$19.00Dec 2, 25$18.79Dec 4, 25$19.70Dec 8, 25$20.59Dec 10, 25$20.63Dec 12, 25$20.73Dec 16, 25$19.84Dec 18, 25$19.48Dec 22, 25$20.35Dec 24, 25$20.69Dec 29, 25$20.00Jan 2, 26$20.00Jan 6, 26$20.90Jan 8, 26$22.03Jan 12, 26$23.15Jan 14, 26$23.66Jan 16, 26$25.22Jan 21, 26$26.04Jan 23, 26$27.15Jan 27, 26$27.69Jan 29, 26$28.24Feb 2, 26$29.03Feb 4, 26$26.37Feb 9, 26$28.35Feb 11, 26$28.58Feb 13, 26$28.49Feb 18, 26$28.65Feb 20, 26$29.17Feb 24, 26$29.63Feb 26, 26$29.99Mar 2, 26$28.61Mar 4, 26$27.72Mar 6, 26$26.96Mar 10, 26$28.65Mar 12, 26$27.10Mar 17, 26$26.92Mar 19, 26$25.37Mar 23, 26$24.60Mar 25, 26$25.00Mar 27, 26$24.69Mar 31, 26$26.59Apr 2, 26$26.63Apr 7, 26$26.40Apr 9, 26$27.19Apr 13, 26$27.12Apr 15, 26$27.54Apr 17, 26$27.46Apr 22, 26$27.85Apr 24, 26$26.44Apr 28, 26$26.72Apr 30, 26$27.48May 4, 26$28.26May 6, 26$29.58May 8, 26$32.64May 12, 26$30.41May 14, 26$30.22May 18, 26$28.07May 20, 26$27.91May 22, 26$29.49May 28, 26$29.65Jun 1, 26$14.51Jun 3, 26$13.14Jun 5, 26$11.21Jun 9, 26$10.98Jun 11, 26$11.00Jun 15, 26$11.61Jun 17, 26$11.30Jun 22, 26$11.67Jun 24, 26$11.56Jun 26, 26$12.00Jul 2, 26$14.12
$10.7152-week range$32.65
Loading valuation history…

Fundamentals

Key fundamentals

$1.7B

Market cap

—

Revenue growth (YoY)

-7492.3%

Gross margin

-$77.8M

Free cash flow (USD)

-$210.9M

Net debt

Net cash position

29.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2020 → 2025

FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$686.0KFY 2025$0.00
$0$0

Free cash flow by year

2020 → 2025

FY 2020$-12.0MFY 2021$-13.9MFY 2022$-28.6MFY 2023$-53.9MFY 2024$-47.7MFY 2025$-62.5M
-$12M-$62.5M

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Jun 1, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingVisionary Innovation PresentationJun 25, 2026Filing
  • Annual reportAnnual Report FiledJun 1, 2026Filing
  • Annual reportAnnual Report FiledMay 14, 2026Filing
  • Annual reportAnnual Report FiledMay 11, 2026Filing
  • Annual reportAnnual Report FiledApr 21, 2026Filing

Questions

Frequently asked questions

What is Oculis Holding AG's market cap?

Oculis Holding AG (OCS) has a market capitalization of $1.7B.

What is OCS's P/E ratio?

A meaningful P/E ratio is not available for OCS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is OCS's price-to-book (P/B) ratio?

OCS trades at 8.42 times book value per share.

Are insiders buying OCS stock?

SEC Form 4 filings show no open-market insider buys at Oculis Holding AG in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

NUVB

Nuvation Bio Inc.

$1.6B

ATAI

Atai Beckley N.V

$1.7B

VIR

Vir Biotechnology, Inc.

$1.6B

RXRX

Recursion Pharmaceuticals, Inc.

$1.6B

INVA

Innoviva, Inc.

$1.6B

VCEL

Vericel Corporation

$1.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.